Volume 6, Issue 1: The Current State of CFTR Modification
e-Cystic Fibrosis Review is a monthly CE series for nurses, nurse practitioners, and others involved in the care of patients with Cystic Fibrosis. It provides updates on the latest research, best practices, and issues currently under debate, as well as a concise review of relevant journal literature.
(Volume 6, Issue 1)
Nurses and health care professionals involved in the care of patients with Cystic Fibrosis.
After participating in this activity, the participant will demonstrate the ability to:
- Describe the long-term benefits of ivacaftor therapy
- Evaluate the effects of ivacaftor in people with non-G551D CFTR mutations
- Explain the impact of lumacaftor/ivacaftor in people with cystic fibrosis due to two F508del CFTR mutations
Dr. Peter Mogayzel reports he has no relevant relationships with a commercial entity.
Dr. Peter Mogayzel reports there will be no discussions of off-label or unapproved uses of drugs or products.
- 1.00 ANCC
- 1.00 Attendance